Neurent Medical, a company pioneering new treatments for chronic inflammatory sino-nasal diseases, has closed a $25 million Series B financing.
 
The round was led by new investor LSP, from its LSP HEF-2 fund, and co-led by Atlantic Bridge, investing from its Growth Fund IV. Fountain Healthcare Partners also participated as a returning investor with strong participation in the round.
 
The financing will support the expansion of the company’s clinical and commercial operations as it prepares for U.S. Food and Drug Administration (FDA) clearance and U.S. commercialization of its proprietary Neuromark Rhinitis Neurolysis Therapy, an in-office treatment for chronic rhinitis.
 
Treating Chronic Rhinitis
Approximately one in four Americans suffer from chronic rhinitis¹, a common condition that results in persistent symptoms including congestion, rhinorrhea, sneezing, and nasal itching. Chronic rhinitis significantly decreases quality of life and can have an adverse effect on sleep quality, mood, and daily activities.
 
The traditional rhinitis patient journey is often frustrating due to limited treatment options. Many chronic rhinitis patients are treated with a combination of continuously prescribed medications with varying and limited effectiveness. In addition to the significant expense, excessive use of these remedies can cause issues such as damage to nasal and bodily tissues, medication dependencies and exacerbated symptoms. Invasive surgical procedures and existing in-office interventions provide mixed outcomes for patients, along with the potential for post-operative complications and pain.
 
Neurent Medical’s proprietary Rhinitis Neurolysis Therapy is designed to comfortably and safely disrupt hyperactive parasympathetic nerves that drive the underlying inflammation. The Neuromark System’s unique design, biofeedback monitoring features and advanced algorithmic controls enable the physician to simultaneously treat multiple nerve branches with a high degree of precision, safety, and patient comfort.
 
“We are grateful for the financial support of this group of highly regarded investors, which will enable us to transition to an international commercial-stage company,” said Neurent Medical CEO and co-founder Brian Shields. “Our technology has the potential to provide an effective, safe and comfortable in-office treatment solution to alleviate the burdensome symptoms of chronic rhinitis, and we are excited that this funding brings us a step closer to offering it to clinicians and patients.”
 
“We are dedicated to nurturing and growing companies with the potential to have a meaningful impact on society, and Neurent Medical is aligned with this mission,” commented Drew Burdon, investment manager at LSP. “The company, with its strong team and pioneering technology, is well-placed to succeed in making a significant difference for the millions of people suffering with chronic rhinitis.”
 
As part of this transaction Drew Burdon of LSP and Gerry Maguire, general partner, Atlantic Bridge, will join Neurent Medical’s Board of Directors.
 
Reference:
¹ Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23-34. PMID: 17153005.